Letter to the editor
Vito D’Alessandro,1 Mario Greco2
1Respiratory Oncology Section – Internal Medicine Department, 2Hematopoietic Stem Cell Transplantation Unit Hematology-Oncology Department, of Scientific Institute, “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo (FG), Italy
We particularly appreciated the recent successful attempt at review of management of tumor lysis syndrome, entitled “Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies”1 which reported some practical management considerations and financial implications of a complex subject. The praiseworthy aim was to give clear and easily applicable indications for clinical practice from recently published off-label treatment studies, using lower and fewer doses of rasburicase than recommended.
View original paper by Kennedy and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]